Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
Objectives Development of novel antiretrovirals aims at reducing long‐term toxicities. Tenofovir disoproxil fumarate (TDF) has been associated with potential nephrotoxicity. The aim of our study was to assess the impact of switching from TDF to tenofovir alafenamide (TAF) on functional nephropathy a...
Gespeichert in:
| Veröffentlicht in: | HIV medicine 2020-07, Vol.21 (6), p.378-385 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 385 |
|---|---|
| container_issue | 6 |
| container_start_page | 378 |
| container_title | HIV medicine |
| container_volume | 21 |
| creator | Schwarze‐Zander, C Piduhn, H Boesecke, C Schlabe, S Stoffel‐Wagner, B Wasmuth, JC Strassburg, CP Rockstroh, JK |
| description | Objectives
Development of novel antiretrovirals aims at reducing long‐term toxicities. Tenofovir disoproxil fumarate (TDF) has been associated with potential nephrotoxicity. The aim of our study was to assess the impact of switching from TDF to tenofovir alafenamide (TAF) on functional nephropathy and lipid parameters in a real‐life setting.
Methods
We retrospectively analysed data from 347 HIV‐infected patients switching from a TDF‐ to a TAF‐containing regimen between April and December 2016. Sociodemographic, clinical and laboratory data were collected at TDF‐to‐TAF switch, and at 3 and 6 months thereafter. Proteinuria and albuminuria were classified according to Kidney Diseases Improving Global Outcomes (KDIGO) guidelines.
Results
At time of switch, moderately and severely increased proteinuria was detected in 32% and 8% of patients, respectively; however, urine dipstick analysis was negative in 84% and 42%, respectively. Moderately and severely increased albuminuria was found in 17% and 3% of patients, respectively. In patients with a urinary protein‐to‐creatinine ratio (UPCR) ≥ 150 mg/g, the mean value declined from 416 mg/g at baseline to 272 mg/g (P |
| doi_str_mv | 10.1111/hiv.12840 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2413484322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2413484322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4540-b7afa15c0561d663e50cd80f7124d25c1be999f973106e6eeb44e6ccc70c9c33</originalsourceid><addsrcrecordid>eNp1kE1PAjEQhhujEUQP_gHTxJOHhX5tl_ViDPGDhMSDxOumdKdSsuxiW0D-vZVF48W5zByeeSbzInRJSZ_GGsztpk_ZUJAj1KVCDhPKcn68n0XCpGQddOb9ghCa8Zycog5nRKYZ5V3kX7c26Lmt33GAujHNxjpcWt-sXPNpK2zWS-VUAByaP4CqlIFaLW0J2NZYYQeqwpU1gD2EEG23eDtXASsXN-cRWq4qq1WwTe3vztGJUZWHi0Pvoenjw3T0nExensaj-0miRSpIMsuUUTTVJJW0lJJDSnQ5JCajTJQs1XQGeZ6bPOOUSJAAMyFAaq0zonPNeQ9dt9r4yscafCgWzdrV8WLBBOViKDhjkbppKe0a7x2YYuVs_HlXUFJ8p1vEdIt9upG9OhjXsyWUv-RPnBEYtMDWVrD731Q8j99a5ReWroVS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2413484322</pqid></control><display><type>article</type><title>Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?</title><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Schwarze‐Zander, C ; Piduhn, H ; Boesecke, C ; Schlabe, S ; Stoffel‐Wagner, B ; Wasmuth, JC ; Strassburg, CP ; Rockstroh, JK</creator><creatorcontrib>Schwarze‐Zander, C ; Piduhn, H ; Boesecke, C ; Schlabe, S ; Stoffel‐Wagner, B ; Wasmuth, JC ; Strassburg, CP ; Rockstroh, JK</creatorcontrib><description><![CDATA[Objectives
Development of novel antiretrovirals aims at reducing long‐term toxicities. Tenofovir disoproxil fumarate (TDF) has been associated with potential nephrotoxicity. The aim of our study was to assess the impact of switching from TDF to tenofovir alafenamide (TAF) on functional nephropathy and lipid parameters in a real‐life setting.
Methods
We retrospectively analysed data from 347 HIV‐infected patients switching from a TDF‐ to a TAF‐containing regimen between April and December 2016. Sociodemographic, clinical and laboratory data were collected at TDF‐to‐TAF switch, and at 3 and 6 months thereafter. Proteinuria and albuminuria were classified according to Kidney Diseases Improving Global Outcomes (KDIGO) guidelines.
Results
At time of switch, moderately and severely increased proteinuria was detected in 32% and 8% of patients, respectively; however, urine dipstick analysis was negative in 84% and 42%, respectively. Moderately and severely increased albuminuria was found in 17% and 3% of patients, respectively. In patients with a urinary protein‐to‐creatinine ratio (UPCR) ≥ 150 mg/g, the mean value declined from 416 mg/g at baseline to 272 mg/g (P < 0.001) and 242 mg/g (P < 0.001) after 3 and 6 months, respectively. Patients with an albumin‐to‐creatinine ratio (UACR) ≥ 30 mg/g showed no significant decrease of albuminuria. Mean total cholesterol increased from 187 mg/dL at baseline to 202 (P < 0.001) and 208 mg/dL (P < 0.001) at 3 and 6 months, respectively, and mean low‐density lipoprotein (LDL) cholesterol increased from 114 mg/dL at baseline to 124 (P < 0.001) and 128 mg/dL (P < 0.001), respectively. As mean high‐density lipoprotein (HDL) cholesterol increased from 50 mg/dL at baseline to 54 (P < 0.001) and 57 mg/dL (P < 0.001) at 3 and 6 months, respectively, the LDL:HDL ratio remained stable.
Conclusions
In an aging HIV‐infected cohort, proteinuria and albuminuria were common findings and were underdiagnosed via urine dipstick. Our real‐life data suggest that laboratory markers of moderately/severely increased proteinuria improved after TDF‐to‐TAF‐switch. Lipid profiles were not aggravated. Long‐term follow‐up is needed to determine the clinical benefit of the TDF‐to‐TAF switch.]]></description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/hiv.12840</identifier><identifier>PMID: 32065713</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aging ; Albumins ; Antiviral agents ; Cholesterol ; Creatinine ; Density ; High density lipoprotein ; HIV ; Human immunodeficiency virus ; Kidney diseases ; Laboratories ; Lipids ; Low density lipoprotein ; Nephropathy ; Proteinuria ; switch ; Switching ; Tenofovir ; tenofovir alafenamide (TAF) ; Toxicity</subject><ispartof>HIV medicine, 2020-07, Vol.21 (6), p.378-385</ispartof><rights>2019 The Authors. published by John Wiley & Sons Ltd on behalf of British HIV Association</rights><rights>2019 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.</rights><rights>2019. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4540-b7afa15c0561d663e50cd80f7124d25c1be999f973106e6eeb44e6ccc70c9c33</citedby><cites>FETCH-LOGICAL-c4540-b7afa15c0561d663e50cd80f7124d25c1be999f973106e6eeb44e6ccc70c9c33</cites><orcidid>0000-0002-2002-8903</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhiv.12840$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhiv.12840$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32065713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwarze‐Zander, C</creatorcontrib><creatorcontrib>Piduhn, H</creatorcontrib><creatorcontrib>Boesecke, C</creatorcontrib><creatorcontrib>Schlabe, S</creatorcontrib><creatorcontrib>Stoffel‐Wagner, B</creatorcontrib><creatorcontrib>Wasmuth, JC</creatorcontrib><creatorcontrib>Strassburg, CP</creatorcontrib><creatorcontrib>Rockstroh, JK</creatorcontrib><title>Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description><![CDATA[Objectives
Development of novel antiretrovirals aims at reducing long‐term toxicities. Tenofovir disoproxil fumarate (TDF) has been associated with potential nephrotoxicity. The aim of our study was to assess the impact of switching from TDF to tenofovir alafenamide (TAF) on functional nephropathy and lipid parameters in a real‐life setting.
Methods
We retrospectively analysed data from 347 HIV‐infected patients switching from a TDF‐ to a TAF‐containing regimen between April and December 2016. Sociodemographic, clinical and laboratory data were collected at TDF‐to‐TAF switch, and at 3 and 6 months thereafter. Proteinuria and albuminuria were classified according to Kidney Diseases Improving Global Outcomes (KDIGO) guidelines.
Results
At time of switch, moderately and severely increased proteinuria was detected in 32% and 8% of patients, respectively; however, urine dipstick analysis was negative in 84% and 42%, respectively. Moderately and severely increased albuminuria was found in 17% and 3% of patients, respectively. In patients with a urinary protein‐to‐creatinine ratio (UPCR) ≥ 150 mg/g, the mean value declined from 416 mg/g at baseline to 272 mg/g (P < 0.001) and 242 mg/g (P < 0.001) after 3 and 6 months, respectively. Patients with an albumin‐to‐creatinine ratio (UACR) ≥ 30 mg/g showed no significant decrease of albuminuria. Mean total cholesterol increased from 187 mg/dL at baseline to 202 (P < 0.001) and 208 mg/dL (P < 0.001) at 3 and 6 months, respectively, and mean low‐density lipoprotein (LDL) cholesterol increased from 114 mg/dL at baseline to 124 (P < 0.001) and 128 mg/dL (P < 0.001), respectively. As mean high‐density lipoprotein (HDL) cholesterol increased from 50 mg/dL at baseline to 54 (P < 0.001) and 57 mg/dL (P < 0.001) at 3 and 6 months, respectively, the LDL:HDL ratio remained stable.
Conclusions
In an aging HIV‐infected cohort, proteinuria and albuminuria were common findings and were underdiagnosed via urine dipstick. Our real‐life data suggest that laboratory markers of moderately/severely increased proteinuria improved after TDF‐to‐TAF‐switch. Lipid profiles were not aggravated. Long‐term follow‐up is needed to determine the clinical benefit of the TDF‐to‐TAF switch.]]></description><subject>Aging</subject><subject>Albumins</subject><subject>Antiviral agents</subject><subject>Cholesterol</subject><subject>Creatinine</subject><subject>Density</subject><subject>High density lipoprotein</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Kidney diseases</subject><subject>Laboratories</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Nephropathy</subject><subject>Proteinuria</subject><subject>switch</subject><subject>Switching</subject><subject>Tenofovir</subject><subject>tenofovir alafenamide (TAF)</subject><subject>Toxicity</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kE1PAjEQhhujEUQP_gHTxJOHhX5tl_ViDPGDhMSDxOumdKdSsuxiW0D-vZVF48W5zByeeSbzInRJSZ_GGsztpk_ZUJAj1KVCDhPKcn68n0XCpGQddOb9ghCa8Zycog5nRKYZ5V3kX7c26Lmt33GAujHNxjpcWt-sXPNpK2zWS-VUAByaP4CqlIFaLW0J2NZYYQeqwpU1gD2EEG23eDtXASsXN-cRWq4qq1WwTe3vztGJUZWHi0Pvoenjw3T0nExensaj-0miRSpIMsuUUTTVJJW0lJJDSnQ5JCajTJQs1XQGeZ6bPOOUSJAAMyFAaq0zonPNeQ9dt9r4yscafCgWzdrV8WLBBOViKDhjkbppKe0a7x2YYuVs_HlXUFJ8p1vEdIt9upG9OhjXsyWUv-RPnBEYtMDWVrD731Q8j99a5ReWroVS</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Schwarze‐Zander, C</creator><creator>Piduhn, H</creator><creator>Boesecke, C</creator><creator>Schlabe, S</creator><creator>Stoffel‐Wagner, B</creator><creator>Wasmuth, JC</creator><creator>Strassburg, CP</creator><creator>Rockstroh, JK</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><orcidid>https://orcid.org/0000-0002-2002-8903</orcidid></search><sort><creationdate>202007</creationdate><title>Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?</title><author>Schwarze‐Zander, C ; Piduhn, H ; Boesecke, C ; Schlabe, S ; Stoffel‐Wagner, B ; Wasmuth, JC ; Strassburg, CP ; Rockstroh, JK</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4540-b7afa15c0561d663e50cd80f7124d25c1be999f973106e6eeb44e6ccc70c9c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aging</topic><topic>Albumins</topic><topic>Antiviral agents</topic><topic>Cholesterol</topic><topic>Creatinine</topic><topic>Density</topic><topic>High density lipoprotein</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Kidney diseases</topic><topic>Laboratories</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Nephropathy</topic><topic>Proteinuria</topic><topic>switch</topic><topic>Switching</topic><topic>Tenofovir</topic><topic>tenofovir alafenamide (TAF)</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwarze‐Zander, C</creatorcontrib><creatorcontrib>Piduhn, H</creatorcontrib><creatorcontrib>Boesecke, C</creatorcontrib><creatorcontrib>Schlabe, S</creatorcontrib><creatorcontrib>Stoffel‐Wagner, B</creatorcontrib><creatorcontrib>Wasmuth, JC</creatorcontrib><creatorcontrib>Strassburg, CP</creatorcontrib><creatorcontrib>Rockstroh, JK</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwarze‐Zander, C</au><au>Piduhn, H</au><au>Boesecke, C</au><au>Schlabe, S</au><au>Stoffel‐Wagner, B</au><au>Wasmuth, JC</au><au>Strassburg, CP</au><au>Rockstroh, JK</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2020-07</date><risdate>2020</risdate><volume>21</volume><issue>6</issue><spage>378</spage><epage>385</epage><pages>378-385</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract><![CDATA[Objectives
Development of novel antiretrovirals aims at reducing long‐term toxicities. Tenofovir disoproxil fumarate (TDF) has been associated with potential nephrotoxicity. The aim of our study was to assess the impact of switching from TDF to tenofovir alafenamide (TAF) on functional nephropathy and lipid parameters in a real‐life setting.
Methods
We retrospectively analysed data from 347 HIV‐infected patients switching from a TDF‐ to a TAF‐containing regimen between April and December 2016. Sociodemographic, clinical and laboratory data were collected at TDF‐to‐TAF switch, and at 3 and 6 months thereafter. Proteinuria and albuminuria were classified according to Kidney Diseases Improving Global Outcomes (KDIGO) guidelines.
Results
At time of switch, moderately and severely increased proteinuria was detected in 32% and 8% of patients, respectively; however, urine dipstick analysis was negative in 84% and 42%, respectively. Moderately and severely increased albuminuria was found in 17% and 3% of patients, respectively. In patients with a urinary protein‐to‐creatinine ratio (UPCR) ≥ 150 mg/g, the mean value declined from 416 mg/g at baseline to 272 mg/g (P < 0.001) and 242 mg/g (P < 0.001) after 3 and 6 months, respectively. Patients with an albumin‐to‐creatinine ratio (UACR) ≥ 30 mg/g showed no significant decrease of albuminuria. Mean total cholesterol increased from 187 mg/dL at baseline to 202 (P < 0.001) and 208 mg/dL (P < 0.001) at 3 and 6 months, respectively, and mean low‐density lipoprotein (LDL) cholesterol increased from 114 mg/dL at baseline to 124 (P < 0.001) and 128 mg/dL (P < 0.001), respectively. As mean high‐density lipoprotein (HDL) cholesterol increased from 50 mg/dL at baseline to 54 (P < 0.001) and 57 mg/dL (P < 0.001) at 3 and 6 months, respectively, the LDL:HDL ratio remained stable.
Conclusions
In an aging HIV‐infected cohort, proteinuria and albuminuria were common findings and were underdiagnosed via urine dipstick. Our real‐life data suggest that laboratory markers of moderately/severely increased proteinuria improved after TDF‐to‐TAF‐switch. Lipid profiles were not aggravated. Long‐term follow‐up is needed to determine the clinical benefit of the TDF‐to‐TAF switch.]]></abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32065713</pmid><doi>10.1111/hiv.12840</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2002-8903</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2020-07, Vol.21 (6), p.378-385 |
| issn | 1464-2662 1468-1293 |
| language | eng |
| recordid | cdi_proquest_journals_2413484322 |
| source | Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Aging Albumins Antiviral agents Cholesterol Creatinine Density High density lipoprotein HIV Human immunodeficiency virus Kidney diseases Laboratories Lipids Low density lipoprotein Nephropathy Proteinuria switch Switching Tenofovir tenofovir alafenamide (TAF) Toxicity |
| title | Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A48%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Switching%20tenofovir%20disoproxil%20fumarate%20to%20tenofovir%20alafenamide%20in%20a%20real%20life%20setting:%20what%20are%20the%20implications?&rft.jtitle=HIV%20medicine&rft.au=Schwarze%E2%80%90Zander,%20C&rft.date=2020-07&rft.volume=21&rft.issue=6&rft.spage=378&rft.epage=385&rft.pages=378-385&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/hiv.12840&rft_dat=%3Cproquest_cross%3E2413484322%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2413484322&rft_id=info:pmid/32065713&rfr_iscdi=true |